Cargando…
Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies
BACKGROUND: We have reported that seroconversion rates after the second dose of mRNA‐based COVID‐19 vaccines for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were 100% and 95% respectively, with no significant difference from healthy controls (HCs).However, there are very limited...
Autores principales: | Mori, Akio, Onozawa, Masahiro, Kobayashi, Mirei, Tsukamoto, Shihori, Senjo, Hajime, Ishio, Takashi, Yokoyama, Emi, Kanaya, Minoru, Izumiyama, Koh, Saito, Makoto, Muraki, Haruna, Morioka, Masanobu, Teshima, Takanori, Kondo, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501249/ https://www.ncbi.nlm.nih.gov/pubmed/37409608 http://dx.doi.org/10.1002/cam4.6314 |
Ejemplares similares
-
Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms
por: Kobayashi, Mirei, et al.
Publicado: (2023) -
Booster Effect of a Third mRNA-Based COVID-19 Vaccine Dose in Patients with Myeloid Malignancies
por: Mori, Akio, et al.
Publicado: (2022) -
Humoral response to mRNA‐based COVID‐19 vaccine in patients with immune thrombocytopenia
por: Mori, Akio, et al.
Publicado: (2022) -
Humoral response to mRNA‐based COVID‐19 vaccine in patients with de novo and pre‐existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination
por: Mori, Akio, et al.
Publicado: (2022) -
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2022)